Literature DB >> 2921175

Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.

B Maciejewski1, H R Withers, J M Taylor, A Hliniak.   

Abstract

In a retrospective study, local control of the primary tumor in 498 squamous cell carcinomas of the oral cavity and oropharynx was analyzed with respect to initial tumor volume, total dose after normalization for variations in fraction size, and to overall treatment time. Primary tumors were grouped into 4 sites, tongue (175), oral cavity including floor of mouth, faucial pillar, soft and hard palate and gingiva (210), tonsil (72) and buccal mucosa (41). Total doses of 60Co irradiation ranged from 30 Gy to 72 Gy, overall treatment times from 15 to 80 days and dose per fraction from 1.8 to 6 Gy. The large number of patients and diversity of dose fractionation patterns permitted assessment of the independent contributions to treatment outcome of stage, fraction size and overall treatment duration. The following conclusions were drawn: (1) Overall treatment time influenced strongly the probability of local tumor control. Over the interval of about 30-55 days used in treating most of this series of patients, an increase of 60 cGy per day, on average, was required for a constant control rate. (2) The increase in dose was attributed to accelerated tumor clonogen growth rate. Such accelerated growth could be a major determinant of failure in protracted regimens. (3) The accelerated rate of regrowth was similar for all tumor sites and stages. (4) The dose for tumor control was relatively independent of variations in fraction size within a range of about 1.6 Gy to 3 Gy: the alpha/beta value in the linear quadratic isoeffect equation was at least 15 Gy. (5) Local control at the primary site required an average of about 3 Gy more for each increase in T stage. This increase most likely reflected an increased number of tumor clonogens, not a decreased tumor cell radiosensitivity. (6) The probability of control at the primary site was less likely if lymph nodes were positive, but this association was only shown to be statistically significant for primaries classified here as oral cavity and oropharynx, not tonsil, tongue or buccal mucosa. (7) After allowing for differences in treatment parameters, especially for heterogeneity in overall treatment times, tumor control probability increased steeply with increase in total dose. (8) A general principle of radiotherapy, at least for squamous carcinomas of head and neck, should be to deliver the desired fractionated dose regimen without unnecessary interruptions and in the shortest time compatible with no reduction in dose below that tolerated by the late-responding normal tissues.

Entities:  

Mesh:

Year:  1989        PMID: 2921175     DOI: 10.1016/0360-3016(89)90503-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.

Authors:  W M Harriss-Phillips; E Bezak; E K Yeoh
Journal:  Br J Radiol       Date:  2011-10       Impact factor: 3.039

Review 2.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

3.  [A linear quadratic analysis of the effect of different fractionation patterns on local tumor control: a study on human squamous-cell carcinomas in nude mice].

Authors:  C Petersen; M Baumann; H H Dubben; H Arps; A Melenkeit; J Helfrich
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

Review 4.  [Current therapy options in recurrent head and neck cancer].

Authors:  A Boehm; G Wichmann; C Mozet; A Dietz
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

Review 5.  Predicting outcomes in radiation oncology--multifactorial decision support systems.

Authors:  Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker
Journal:  Nat Rev Clin Oncol       Date:  2012-11-20       Impact factor: 66.675

6.  [A century of development in radiation biology. Basic principles of targeted and efficient radiotherapy].

Authors:  C Streffer; T Herrmannn
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

Review 7.  Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Authors:  Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li
Journal:  Radiother Oncol       Date:  2016-11-18       Impact factor: 6.280

8.  Effectiveness of PET/CT with (18)F-fluorothymidine in the staging of patients with squamous cell head and neck carcinomas before radiotherapy.

Authors:  Radovan Vojtíšek; Jiří Ferda; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2015-02-17

9.  Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.

Authors:  Mary E Platek; Susan A McCloskey; Myra Cruz; Mark S Burke; Mary E Reid; Gregory E Wilding; Nestor R Rigual; Saurin R Popat; Thom R Loree; Vishal Gupta; Graham W Warren; Maureen Sullivan; Wesley L Hicks; Anurag K Singh
Journal:  Head Neck       Date:  2012-05-22       Impact factor: 3.147

10.  Acute mucosal reactions in patients with head and neck cancer. Three patterns of mucositis observed during radiotherapy.

Authors:  A Wygoda; T Rutkowski; M Hutnik; K Składowski; M Goleń; B Pilecki
Journal:  Strahlenther Onkol       Date:  2013-05-23       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.